sameAs
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract SurgeryPediatric Zylet Safety and Efficacy StudyZylet vs TobraDex in BlepharokeratoconjunctivitisComparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens ImplantationEfficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/BlepharitisLoteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryEvaluation of the Safety, Systemic Pharmacokinetics, and TolerabilityLoteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic ConjunctivitisClinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract SurgeryLoteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen ChallengeLoteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of BlepharokeratoconjunctivitisEfficacy of Loteprednol Ointment Following Eyelid SurgerySafety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric BlepharoconjunctivitisLoteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract SurgeryEvaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) ModelSafety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainA Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular EdemaTopical Steroid Treatment For Dry EyeSafety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland DiseaseSafety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseLotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis SiccaComparison the Effects of Dexamethasone and Loteprednol on Epithelial HealingAntibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and InfectionChanges of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol EtabonateA Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single InstillationRandomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following PhacoemulsificationEvaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryLoteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryA Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/TobramycinUse of Loteprednol for Contact Lens Intolerance and DrynessIntraocular Pressure With Loteprednol and DexamethasoneStudy of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract SurgeryA Novel Combined Therapy for Refractory Vernal KeratoconjunctivitisEvaluation of Ocular Surface Inflammatory Mediators Effected by LotemaxSafety and Efficacy of KPI-121 in Subjects With Postsurgical InflammationTreatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
P4844
Q101991-F167B2A0-2F5F-4291-9FE1-CDE5FFCE5323Q18555085-073E38C7-7DE3-44B3-8345-24D8B08D830CQ18558195-6ED3CABE-F098-4C37-96AC-A936FFB55F36Q2346396-266D4BBD-C3B4-4801-852B-9A3CD41265C6Q3686833-F193F20E-07AD-4883-BD51-A07AE4149639Q486485-BD8ADDC5-D079-4B8E-806D-E0BDF8CA8A3FQ757838-518EDAAA-0789-4D93-A962-3831CBF08773Q831530-B4F81E31-F82E-47F5-B330-7E47B1D41030
P2176
Q61914407-1866ADC3-632B-4839-B3C5-0DD684D7BFA3Q61921960-F725D236-32F5-4439-A1C9-F83720229C3AQ61924291-556CA5B3-C39B-45FB-B9A6-EA2520301DCFQ61934061-66A9DF6D-C459-4064-9A33-2BB69184659BQ61966028-57114555-56B6-4B60-AA77-EBA9A742D3BFQ61969573-41156957-72CE-4B6E-82F3-C14109DDF7F6Q63229692-CC874CEF-E09A-421C-A80E-576C2F1B2EB6Q63320995-8B9F1C88-4E23-448D-8AF5-BA270FE631A8Q63321996-F5F4DA06-DADF-45E5-85A2-174E23C1C9B8Q63336842-97581918-AF92-45A2-BB59-E7674CFB1D5BQ63833970-EEB5EB85-F865-42F8-82A3-5E1A65C557FCQ63838388-225F0F86-02F5-4B20-9B6E-0C7295B4F76DQ63841183-A6A63D02-A36C-4D54-AE8C-680F3DD5BE9AQ64041963-C52B6DF3-9C18-4522-A99A-D3AB479350B2Q64043165-41E342C3-194E-4AE1-A258-3F49AF521A66Q64045180-DB743A10-9976-489D-AADD-2E310F6A3876Q64184505-C47F1708-31E6-45AE-AC22-9449215313DAQ64349530-ACA0F5BF-9A69-4A2F-A423-B15CC49EABE2Q64603119-4B928E55-B626-4F8A-9F7B-C20A2293330EQ64604535-3BBA4683-3B62-467D-AB72-1AC1A66F954FQ64604565-CD34D106-D714-405A-A6EE-03889D6BB553Q64607833-4E81FD98-788F-4698-8BEC-E90A6C89876DQ64625414-4C4F8FEE-44AF-4AD5-ACCB-D868349F2970Q64637710-574BAE23-9A12-4CFD-A824-18A5543A96C7Q64638285-E45F0712-918E-4782-8034-D5AC537342B9Q64640792-F2B31348-2FB7-428D-86A5-2007A0A6E681Q64647778-E3AABF6F-8AAA-42B6-A793-8646980F5F5EQ64647973-D7C77AEE-6457-4921-9F54-AA96E1D449ECQ64650922-437732F9-8517-43E1-9A43-3F29B582E84AQ64652345-CAF793DE-5750-49F8-9A9B-00B19F343C9AQ64656016-970CEB0A-562C-4BE4-A7AA-8862D70CAA4DQ64660000-2AAEE568-4278-4076-8A21-67A463306F97Q64695035-843606E8-9682-40AB-8F8F-8DD2117272E0Q64695634-133BA242-5AD6-417D-A3BA-328DC17A1EA2Q64710709-5458CA4D-034F-450D-9338-E5EE821E75CFQ64796700-5B92A7E5-E373-4206-BE75-10D2D59668F2Q64804991-DD468E1C-A22E-4089-BAA6-15C3C439D9C8Q65353683-A9F42D50-45F2-4B44-B81D-1DE76982B2D6Q65355546-2C3ED0F4-B714-49F1-AECF-C65DBE37BF9AQ65370633-AA3F7630-FE8B-4BE8-9F3D-D92FBF8250AC
P4844
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Loteprednol etabonate
@en
Loteprednol
@sh
Loteprednol
@sr
Loteprednol
@vi
loteprednol
@nn
loteprednolo
@it
ロテプレドノール
@ja
type
label
Loteprednol etabonate
@en
Loteprednol
@sh
Loteprednol
@sr
Loteprednol
@vi
loteprednol
@nn
loteprednolo
@it
ロテプレドノール
@ja
altLabel
loteprednol etabonate
@en
loteprednoletabonat
@nn
prefLabel
Loteprednol etabonate
@en
Loteprednol
@sh
Loteprednol
@sr
Loteprednol
@vi
loteprednol
@nn
loteprednolo
@it
ロテプレドノール
@ja
P486
P592
P6366
P661
P662
P665
P683
P1579
P2017
CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
P2115
N0000148544
P231
82034-46-6
P232
P233
CCOC(=O)OC1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)C(=O)OCCl